Discovering novel chemotherapeutic drugs for the third millennium
- PMID: 10711243
- DOI: 10.1016/s0959-8049(99)00280-4
Discovering novel chemotherapeutic drugs for the third millennium
Abstract
There is enormous potential for the discovery of innovative cancer drugs with improved efficacy and selectivity for the third millennium. In this review we show how novel mechanism-based agents are being discovered by focusing on the molecular targets and pathways that are causally involved in cancer formation, maintenance and progression. We also show how new technologies, from genomics through high through-put bioscience, combinatorial chemistry, rational drug design and molecular pharmacodynamic and imaging techniques, are accelerating the pace of cancer drug discovery. The process of contemporary small molecule drug discovery is described and progress and current issues are reviewed. New and potential targets and pathways for therapeutic intervention are illustrated. The first examples of a new generation of molecular therapeutics are now entering hypothesis-testing clinical trials and showing activity. The early years of the new millennium will see a range of exciting new agents moving from bench to bedside and beginning to impact on the management and cure of cancer.
Similar articles
-
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. doi: 10.1007/s00280-003-0593-0. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819933 Review.
-
Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.Cold Spring Harb Symp Quant Biol. 2005;70:499-515. doi: 10.1101/sqb.2005.70.020. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869789
-
From bench top to bedside.Science. 1997 Nov 7;278(5340):1036-9. doi: 10.1126/science.278.5340.1036. Science. 1997. PMID: 9381201 No abstract available.
-
Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.Am J Pharmacogenomics. 2005;5(3):173-90. doi: 10.2165/00129785-200505030-00004. Am J Pharmacogenomics. 2005. PMID: 15952871 Review.
-
The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.Clin Oncol (R Coll Radiol). 1996;8(3):186-9. Clin Oncol (R Coll Radiol). 1996. PMID: 8814375 Review. No abstract available.
Cited by
-
Green synthesis of gold nanoparticles and their anticancer activity.Cancer Nanotechnol. 2013;4(4-5):91-98. doi: 10.1007/s12645-013-0040-9. Epub 2013 Jun 5. Cancer Nanotechnol. 2013. PMID: 26069504 Free PMC article.
-
Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility.J Clin Invest. 2002 Oct;110(8):1123-32. doi: 10.1172/JCI16029. J Clin Invest. 2002. PMID: 12393848 Free PMC article.
-
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.Br J Cancer. 2003 Mar 24;88(6):848-54. doi: 10.1038/sj.bjc.6600789. Br J Cancer. 2003. PMID: 12644821 Free PMC article.
-
Virtual Combinatorial Chemistry and Pharmacological Screening: A Short Guide to Drug Design.Int J Mol Sci. 2022 Jan 30;23(3):1620. doi: 10.3390/ijms23031620. Int J Mol Sci. 2022. PMID: 35163543 Free PMC article. Review.
-
Synthesis of novel 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole derivatives as antiproliferative agents: a structure-activity relationship study.Invest New Drugs. 2009 Dec;27(6):534-42. doi: 10.1007/s10637-008-9205-5. Epub 2008 Dec 6. Invest New Drugs. 2009. PMID: 19066725
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources